Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy
- 1 May 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (9) , 3236-3242
- https://doi.org/10.1158/0008-5472.can-03-3516
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively kill neoplastic cells and control of its activity could enhance tumor therapy. We have developed means to control the secretion of a novel recombinant (r) TRAIL fusion protein using a viral protease. This system uses the endoplasmic reticulum (ER) as a storage depot for rTRAIL, because TRAIL acts by binding to its cognate receptors on the cell surface. We have engineered two TRAIL variants: (a) a secretable form that enhances apoptosis via a bystander effect; and (b) an ER-targeted TRAIL that is retained in the ER until selectively released by the viral protease. Gene delivery can be monitored in vivo by systemic administration of a near infrared fluorescent (NIRF) probe activated by the protease. This study serves as a template for design of recombinant proteins to enhance and control apoptosis of tumor cells via specific viral proteases and for use of viral proteases as in vivo reporters for cancer therapy.Keywords
This publication has 32 references indexed in Scilit:
- In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced GliomasCancer Research, 2004
- IFNγ sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expressionOncogene, 2003
- Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivoOncogene, 2003
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccineVaccine, 2002
- Regression of Human Mammary Adenocarcinoma by Systemic Administration of a Recombinant Gene Encoding the hFlex-TRAIL Fusion ProteinMolecular Therapy, 2001
- Regulation of Protein Secretion Through Controlled Aggregation in the Endoplasmic ReticulumScience, 2000
- APO2 ligand: a novel lethal weapon against malignant glioma?FEBS Letters, 1998
- Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cellsCell, 1993
- A C-terminal signal prevents secretion of luminal ER proteinsPublished by Elsevier ,1987